AU1208892A - Immunotoxin from anti-cd5 monoclonal antibodies - Google Patents
Immunotoxin from anti-cd5 monoclonal antibodiesInfo
- Publication number
- AU1208892A AU1208892A AU12088/92A AU1208892A AU1208892A AU 1208892 A AU1208892 A AU 1208892A AU 12088/92 A AU12088/92 A AU 12088/92A AU 1208892 A AU1208892 A AU 1208892A AU 1208892 A AU1208892 A AU 1208892A
- Authority
- AU
- Australia
- Prior art keywords
- immunotoxin
- monoclonal antibodies
- monoclonal
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI91A000491 | 1991-02-26 | ||
| ITMI910491A IT1249051B (it) | 1991-02-26 | 1991-02-26 | Immunotossina da anticorpi monoclonali anti-cd5 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU1208892A true AU1208892A (en) | 1992-09-15 |
Family
ID=11358745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU12088/92A Abandoned AU1208892A (en) | 1991-02-26 | 1992-02-18 | Immunotoxin from anti-cd5 monoclonal antibodies |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0577612A1 (it) |
| AU (1) | AU1208892A (it) |
| IT (1) | IT1249051B (it) |
| WO (1) | WO1992014491A1 (it) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837491A (en) * | 1991-11-04 | 1998-11-17 | Xoma Corporation | Polynucleotides encoding gelonin sequences |
| US5621083A (en) * | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
| US6146850A (en) * | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
| CA3082310A1 (en) | 2017-11-29 | 2019-06-06 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd5+ cells |
| BR112021021165A2 (pt) | 2019-04-24 | 2022-01-04 | Heidelberg Pharma Res Gmbh | Conjugados anticorpo-fármaco de amatoxina e uso dos mesmos |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4363799A (en) * | 1979-03-20 | 1982-12-14 | Ortho Pharmaceutical Corporation | Monoclonal antibody to human T cells, and methods for preparing same |
| FR2577135B1 (fr) * | 1985-02-13 | 1989-12-15 | Sanofi Sa | Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques |
| DE3581210D1 (de) * | 1985-03-04 | 1991-02-07 | Dana Farber Cancer Inst Inc | Immunotoxin und herstellung. |
| US4831122A (en) * | 1986-01-09 | 1989-05-16 | Regents Of The University Of Minnesota | Radioimmunotoxins |
| AU633251B2 (en) * | 1988-02-03 | 1993-01-28 | Xoma Corporation | Therapeutic use of anti-t cell immunotoxin for autoimmune diseases |
| JPH03503164A (ja) * | 1988-02-03 | 1991-07-18 | エクソウマ コーポレーション | 抗‐パンt‐細胞イムノトキシン組成物による免疫抑制 |
| WO1989011871A1 (en) * | 1988-06-01 | 1989-12-14 | Cetus Corporation | One-step chromatographic purification of immunotoxin conjugates using a thiophilic matrix |
-
1991
- 1991-02-26 IT ITMI910491A patent/IT1249051B/it active IP Right Grant
-
1992
- 1992-02-18 WO PCT/EP1992/000338 patent/WO1992014491A1/en not_active Ceased
- 1992-02-18 AU AU12088/92A patent/AU1208892A/en not_active Abandoned
- 1992-02-18 EP EP92904825A patent/EP0577612A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| IT1249051B (it) | 1995-02-11 |
| ITMI910491A1 (it) | 1992-08-26 |
| WO1992014491A1 (en) | 1992-09-03 |
| ITMI910491A0 (it) | 1991-02-26 |
| EP0577612A1 (en) | 1994-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU4042195A (en) | Anti-alphaV-integrin monoclonal antibody | |
| AU4618193A (en) | Humanized antibodies | |
| IL99363A0 (en) | Pharmaceutical compositions comprising homoconjugated monoclonal antibodies | |
| AU4025193A (en) | Humanized C-erbB-2 specific antibodies | |
| PL309249A1 (en) | Humanised antibodies against l-selectin | |
| AU7411896A (en) | Bispecific antibody heterodimers | |
| AU1289795A (en) | Monoclonal antibodies specific for human interleukin-5 | |
| AU5283893A (en) | Recombinant humanized anti-cytomegalovirus antibodies | |
| AU6080794A (en) | Antibodies directed against binding-associated epitopes | |
| EP0578515A3 (en) | Humanized monoclonal antibodies. | |
| EP0580859A4 (en) | Anti-eda monoclonal antibody | |
| GB9412166D0 (en) | Retargetting antibodies | |
| EP0683675A4 (en) | HUMAN MONOCLONAL ANTIBODIES AGAINST CYTOMEGALOVIRUS. | |
| EP0506523A3 (en) | Monoclonal antibodies | |
| AU1025692A (en) | Novel chimeric antiidiotypic monoclonal antibodies | |
| AU1208892A (en) | Immunotoxin from anti-cd5 monoclonal antibodies | |
| EP0562125A4 (en) | Antibody composition. | |
| AU4195793A (en) | Bispecific antibody | |
| AU8547291A (en) | Monoclonal antibodies against tenascin | |
| AU1809695A (en) | Tumor associated monoclonal antibody 123av16 | |
| EP0508282A3 (en) | Anti-idiotypic monoclonal antibodies | |
| EP0654532A4 (en) | ANTIMUCOGLYCOPROTEIN MONOCLONAL ANTIBODIES. | |
| AU3008892A (en) | Tumor associated monoclonal antibody 88bv59 | |
| AU7862291A (en) | Modified antibodies | |
| EP0671924A4 (en) | DIGITALIN LIKE COMPOUNDS. |